Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

This study is currently recruiting participants.

Verified by Atrium Medical Center, September 2005

Sponsored by:	Atrium Medical Center
Information provided by:	Atrium Medical Center
ClinicalTrials.gov Identifier:	NCT00206193

Purpose

The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.

Condition	Intervention	Phase
Abortion, Induced	Drug: mifepristone Drug: misoprostol Drug: sulprostone	Phase II

Drug Information available for: Mifepristone Misoprostol Sulprostone

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female

Criteria

Inclusion Criteria:

Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria:

Women with liver/kidney disease
Women on long-term use of corticosteroids (> 6 months)
Cardiovascular problems
Therapy-resistant diabetic women
Therapy-resistant asthma/bronchitis
Thalassemia
Ulcerative colitis
Peptic ulcer disease
Glaucoma
Porphyria
Allergic reaction to prostaglandin or mifepristone
Women with a prior caesarian section or women with contractions at the start of the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00206193

Contacts

Contact: Suzanne HW Vonken, Dr.	003145-5766666 ext 466825	svonken@gmail.com
Contact: F Roumen, Dr.	003145-5766666 ext 466509

Locations

Netherlands, Limburg
Atrium Medisch Centrum	Recruiting
Heerlen, Limburg, Netherlands
Contact: Suzanne HW Vonken, Dr. 045-5766666(6825)
Principal Investigator: Suzanne HW Vonken, Dr.

Sponsors and Collaborators

Atrium Medical Center

Investigators

Study Director:

F Roumen, Dr.

Atrium Medisch Centrum Heerlen

More Information

Study ID Numbers:	TOP-protocol
Study First Received:	September 13, 2005
Last Updated:	October 29, 2007
ClinicalTrials.gov Identifier:	NCT00206193
Health Authority:	United States: Food and Drug Administration

Keywords provided by Atrium Medical Center:

termination of pregnancy

Study placed in the following topic categories:

Misoprostol
Mifepristone
Sulprostone

Additional relevant MeSH terms:

Abortifacient Agents, Steroidal
Contraceptives, Postcoital, Synthetic
Oxytocics
Contraceptive Agents
Hormone Antagonists
Contraceptives, Oral
Physiological Effects of Drugs
Gastrointestinal Agents
Contraceptive Agents, Female
Hormones, Hormone Substitutes, and Hormone Antagonists

Reproductive Control Agents
Abortifacient Agents, Nonsteroidal
Contraceptives, Postcoital
Luteolytic Agents
Pharmacologic Actions
Therapeutic Uses
Anti-Ulcer Agents
Abortifacient Agents
Menstruation-Inducing Agents
Contraceptives, Oral, Synthetic

ClinicalTrials.gov processed this record on January 16, 2009